Physician profile
Neil Stuart Shechtman
NPI 1154340156
$3,355.19
in general payments reported to CMS, 2019-2025
28 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $758 · 2020: $851 · 2021: $872 · 2022: $316 · 2023: $199 · 2024: $242 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $558.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $626.78 | 2019-2024 | Ozempic |
| Lilly USA, LLC | $351.71 | 2019-2024 | Mounjaro |
| Amgen INC. | $294.22 | 2019-2025 | Otezla, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $243.03 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Janssen Pharmaceuticals, INC | $211.48 | 2020-2023 | Xarelto |
| Exact Sciences Corporation | $208.86 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $187.45 | 2019-2021 | |
| Abbott Laboratories | $182.76 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $167.34 | 2019-2020 | |
| Dexcom, INC. | $137.99 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.75 | 2021-2022 | |
| Mylan Specialty L.P. | $97.82 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.58 | 2022 | |
| Pfizer INC. | $80.03 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.39 | 2022-2023 | Glassia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $63.62 | 2021 | |
| Glaxosmithkline, LLC. | $33.85 | 2019 | |
| Sunovion Pharmaceuticals INC. | $29.22 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $23.98 | 2020-2022 | |
| Allergan, INC. | $21.16 | 2020 | |
| Esperion Therapeutics, INC. | $19.06 | 2020 | |
| Almatica Pharma LLC | $17.94 | 2021 | |
| Horizon Therapeutics Plc | $17.85 | 2021 | |
| Corcept Therapeutics | $15.58 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $15.23 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.16 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.33 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Shechtman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.